GSK in talks to buy cancer drugmaker Nuvalent for over $9 bln, FT reports

Investing.com Gold reports: GSK in talks to buy cancer drugmaker Nuvalent for over $9 bln, FT reports. Full body text was unavailable at ingest time, so this brief is based on headline context.